Hematopoietic stem cell transplantation and quality of life during the first year of treatment

Objective: to evaluate the quality of life of adult patients with hematological cancer comparing Hematopoietic Stem Cell Transplantation modalities during the first year of treatment. Method: this is an observational and longitudinal research with 55 participants. Data collection was performed in six steps: before transplantation, pancytopenia, before hospital discharge, after 100, 180 and 360 days, in a reference hospital in Brazil for this treatment. The international instruments Quality of Life Questionnaire - Core 30 and Functional Assessment Cancer Therapy - Bone Marrow Transplantation were validated and translated into Portuguese (Brazil). Results: the mean age of participants was 36 years, 65% (n = 36) had leukemia diagnosis and 71% (n = 39) had undergone allogenic transplantation. In the Quality of Life Questionnarie - Core30 instrument, the pain symptom was significant between the first and second stages, and loss of appetite between the third and fourth stages, both in the allogenic group. In the Functional Assessment Cancer Therapy - Bone Marrow Transplantation, the functional well-being domain was significant between the third and fourth stages, also in the allogenic group. Conclusions: although the aggressiveness of treatment affects quality of life, patients consider it satisfactory after the first year. There are few significant differences between autologous and allogenic patients, and both groups have recovered in the course of the process.Objetivo: evaluar la calidad de vida de los pacientes adultos con cáncer hematológico comparando las modalidades de Trasplante de Células Tronco Hematopoyéticas durante el primer año de tratamiento. Método: investigación observacional, longitudinal, con 55 participantes; recogida de datos en seis etapas: pre trasplante, pancitopenia, pre alta hospitalaria, después de 100, 180 y 360 días, en un hospital referencia en Brasil para este tratamiento. Fueron utilizados los instrumentos internacionales Quality of Life Questionnarie-Core 30 y Functional Assessment Cancer Therapy- Bone Marrow Transplantation, validados y traducidos para la lengua portuguesa (Brasil). Resultados: media de edad 36 años, 65% (n=36) presentaron diagnóstico de leucemia y 71% (n=39) se sometieron al trasplante alogénico. En el instrumento Quality of Life Questionnarie – Core30, el síntoma dolor fue significativo entre la primera y la segunda etapa, y la pérdida de apetito entre la tercera y la cuarta etapa, ambos en el grupo alogénico. En el instrumento Functional Assessment Cancer Therapy- Bone Marrow Transplantation el dominio bienestar funcional se presentó significativo entre la tercera y la cuarta etapa, también en el grupo alogénico. Conclusiones: a pesar de que la agresividad del tratamiento afecta la calidad de vida, los pacientes la consideraron satisfactoria después del primer año. Existen pocas diferencias significativas entre autólogos y alogénicos, y ambos se recuperan en el transcurso del proceso.Objetivo: avaliar a qualidade de vida dos pacientes adultos com câncer hematológico comparando as modalidades de Transplante de Células-Tronco Hematopoiéticas durante o primeiro ano de tratamento. Método: pesquisa observacional, longitudinal, com 55 participantes; coleta de dados em seis etapas: pré-transplante, pancitopenia, pré-alta hospitalar, pós 100, 180 e 360 dias, em um hospital referência no Brasil para esse tratamento. Foram utilizados os instrumentos internacionais Quality of Life Questionnarie-Core 30 e Functional Assessment Cancer TherapyBone Marrow Transplantation, validados e traduzidos para a língua portuguesa (Brasil). Resultados: média de idade 36 anos, 65% (n=36) apresentaram diagnóstico de leucemia e 71% (n=39) submeteram-se ao transplante alogênico. No instrumento Quality of Life Questionnarie – Core30, o sintoma dor foi significante entre a primeira e a segunda etapa, e perda de apetite entre a terceira e a quarta etapa, ambos no grupo alogênico. No instrumento Functional Assessment Cancer Therapy- Bone Marrow Transplantation, o domínio bem-estar funcional apresentou-se significante entre a terceira e a quarta etapa, também no grupo alogênico. Conclusões: embora a agressividade do tratamento afete a qualidade de vida, os pacientes a consideram satisfatória após o primeiro ano. Há poucas diferenças significantes entre autólogos e alogênicos, e ambos se recuperam no decorrer do processo

Hematopoietic stem cell transplantation and quality of life during the first year of treatment

ABSTRACT Objective: to evaluate the quality of life of adult patients with hematological cancer comparing Hematopoietic Stem Cell Transplantation modalities during the first year of treatment. Method: this is an observational and longitudinal research with 55 participants. Data collection was performed in six steps: before transplantation, pancytopenia, before hospital discharge, after 100, 180 and 360 days, in a reference hospital in Brazil for this treatment. The international instruments Quality of Life Questionnaire - Core 30 and Functional Assessment Cancer Therapy - Bone Marrow Transplantation were validated and translated into Portuguese (Brazil). Results: the mean age of participants was 36 years, 65% (n = 36) had leukemia diagnosis and 71% (n = 39) had undergone allogenic transplantation. In the Quality of Life Questionnarie - Core30 instrument, the pain symptom was significant between the first and second stages, and loss of appetite between the third and fourth stages, both in the allogenic group. In the Functional Assessment Cancer Therapy - Bone Marrow Transplantation, the functional well-being domain was significant between the third and fourth stages, also in the allogenic group. Conclusions: although the aggressiveness of treatment affects quality of life, patients consider it satisfactory after the first year. There are few significant differences between autologous and allogenic patients, and both groups have recovered in the course of the process